Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Lineage Cell Therapeutics Inc (LCTX)
Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,524
  • Shares Outstanding, K 170,174
  • Annual Sales, $ 14,700 K
  • Annual Income, $ -26,270 K
  • 60-Month Beta 1.68
  • Price/Sales 14.81
  • Price/Cash Flow N/A
  • Price/Book 3.25
Trade LCTX with:

Options Overview Details

View History
  • Implied Volatility 637.27% ( +326.56%)
  • Historical Volatility 45.78%
  • IV Percentile 98%
  • IV Rank 53.10%
  • IV High 1,178.79% on 09/16/22
  • IV Low 24.18% on 05/15/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 3,811
  • Open Int (30-Day) 3,736

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.04
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2700 +1.57%
on 05/26/23
1.5100 -14.57%
on 05/10/23
-0.0600 (-4.44%)
since 04/26/23
3-Month
1.2300 +4.88%
on 02/27/23
1.5500 -16.77%
on 04/03/23
+0.0700 (+5.74%)
since 02/24/23
52-Week
1.0200 +26.47%
on 10/19/22
1.7900 -27.93%
on 08/05/22
+0.0400 (+3.20%)
since 05/26/22

Most Recent Stories

More News
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 550% and 6.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PBYI : 3.19 (-0.31%)
LCTX : 1.2900 (+0.78%)
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 1.2900 (+0.78%)
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging...

LCTX : 1.2900 (+0.78%)
Lineage to Present at 2023 AAPS National Biotechnology Conference

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley,...

LCTX : 1.2900 (+0.78%)
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation...

LCTX : 1.2900 (+0.78%)
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a...

LCTX : 1.2900 (+0.78%)
Lineage Cell (LCTX) Reports Q4 Loss, Misses Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 35.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 1.2900 (+0.78%)
MIRO : 0.9500 (unch)
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating...

LCTX : 1.2900 (+0.78%)
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging...

LCTX : 1.2900 (+0.78%)
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

EYPT : 5.93 (unch)
LCTX : 1.2900 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.3333
2nd Resistance Point 1.3167
1st Resistance Point 1.3033
Last Price 1.2900
1st Support Level 1.2733
2nd Support Level 1.2567
3rd Support Level 1.2433

See More

52-Week High 1.7900
Fibonacci 61.8% 1.4959
Fibonacci 50% 1.4050
Fibonacci 38.2% 1.3141
Last Price 1.2900
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar